In this week’s video, Dr. Brian Durie explains why MRD testing is important for assessing the results of clinical trials, but is not yet ready for the clinic.

In clinical trials, the new criteria are essential to assess new drug combination therapies.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at


Previous Post
Preview of the Black Swan Research Initiative’s First US Cure Trial
Next Post
Darzalex® (daratumumab): more very good news and a caution

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.